CVRx (CVRX)

• Market cap: $294M
• 1 day: 3.33%
• 5 days: -4.65%
• 1 month: -10.43%
• 3 months: 32.93%
• 6 months: 9.00%
• Year to date: -60.28%
• 1 year: -49.22%
• 5 years: -56.75%
• 10 years: -56.75%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Employees: 200

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

54% more call options, than puts

Call options by funds: $653K | Put options by funds: $425K

16% more funds holding

Funds holding: 73 [Q2] → 85 (+12) [Q3]

2.86% more ownership

Funds ownership: 61.96% [Q2] → 64.82% (+2.86%) [Q3]

23% less capital invested

Capital invested by funds: $160M [Q2] → $124M (-$36.4M) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 16% upside
• Avg. target: $17.40 44% upside
• High target: $22 82% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target	82% upside $22	Buy Maintained	9 Dec 2024
Craig-Hallum Alexander Nowak 64% 1-year accuracy 9 / 14 met price target	65% upside $20	Buy Maintained	4 Nov 2024
Lake Street Frank Takkinen 58% 1-year accuracy 11 / 19 met price target	24% upside $15	Buy Maintained	30 Oct 2024
Piper Sandler Matt O'Brien 57% 1-year accuracy 29 / 51 met price target	32% upside $16	Overweight Reiterated	30 Oct 2024
Cantor Fitzgerald Ross Osborn 49% 1-year accuracy 23 / 47 met price target	16% upside $14	Overweight Reiterated	23 Oct 2024